NCT01891669 - A Study Of PF-06263507 In Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 8, 2013

Primary Completion Date

June 29, 2015

Study Completion Date

June 29, 2015

Conditions

NeoplasmsCarcinoma, Non Small Cell LungBreast NeoplasmsOvarian Neoplasms

Interventions

DRUG

PF-06263507

Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.

DRUG

PF-06263507

Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.

Trial Locations (4)

19111

Fox Chase Cancer Center, Philadelphia

48201

Karmanos Cancer Institute, Detroit

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston